Projection of age of individuals living with HIV and time since ART initiation in 2030: estimates for France.
HIV epidemiology
ageing
demographic profile
life expectancy
modelling
time since treatment initiation
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
19
01
2022
accepted:
01
08
2022
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
4
10
2022
Statut:
ppublish
Résumé
Thanks to antiretroviral treatment (ART), people living with HIV (PLHIV) are living longer and ageing. However, ageing involves increased risks of co-morbidities, which also depend on when PLHIV individuals started ART. To tackle the HIV age-related upcoming challenges, knowledge of the current and future age structure of the HIV population is needed. Here, we forecast the demographic profile of the adult population living with diagnosed HIV (aPLdHIV) in France until 2030, accounting for the impact of the ART initiation period on mortality. We used national data from the French Hospital Database on HIV (ANRS CO4-FHDH) and a sample of the National Health Data System to, first, characterize the aPLdHIV in 2018 and estimate their mortality rates according to age, sex and ART initiation period. Second, we used national HIV surveillance data to define three scenarios for the numbers of newly diagnosed HIV cases over 2019-2030: 30% decrease in HIV cases (S1), status quo situation (S2) and epidemic elimination (S3). We then combined these data using a matrix model, to project the age structure of aPLdHIV and time since ART initiation. In 2018, there was an estimated 161,125 aPLdHIV (33% women), of which 55% were aged 50 or older (50+), 22% aged 60+ and 8% aged 70+. In 2030, the aPLdHIV would grow to 195,246 for S1, 207,972 for S2 and 167,221 for S3. Whatever the scenario, in 2030, the estimated median time since ART initiation would increase and age distribution would shift towards older ages: with 65-72% aPLdHIV aged 50+, 42-48% 60+ and 17-19% 70+. This corresponds to ∼83,400 aPLdHIV (28% women) aged 60+, among which ∼69% started ART more than 20 years ago (i.e. before 2010) and ∼39% ≥30 years ago (i.e. before 2000), and to ∼33,100 aPLdHIV (27% women) aged 70+, among which ∼72% started ART ≥20 years ago and ∼43% ≥30 years ago. By 2030, in France, close to 20% of the aPLdHIV will be aged 70+, of which >40% would have started ART more than 30 years ago. These estimates are essential to adapt co-morbidities screening and anticipate resource provision in the aged care sector.
Identifiants
pubmed: 36176023
doi: 10.1002/jia2.25986
pmc: PMC9523002
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25986Informations de copyright
© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):e115-e116
pubmed: 30272638
Lancet HIV. 2022 Apr;9(4):e269-e280
pubmed: 35218732
Epidemiol Infect. 2006 Dec;134(6):1345-52
pubmed: 16690003
Ann Epidemiol. 2022 Jan;65:46-55
pubmed: 34627998
AIDS Care. 2017 Dec;29(12):1543-1550
pubmed: 28395528
Arch Intern Med. 2012 Nov 12;172(20):1591-8
pubmed: 23045164
Lancet Healthy Longev. 2021 Oct;2(10):e639-e650
pubmed: 34870254
Lancet HIV. 2015 Jul;2(7):e288-98
pubmed: 26423253
Int J Epidemiol. 2014 Oct;43(5):1425-36
pubmed: 24550249
Clin Infect Dis. 2021 Apr 26;72(8):1301-1311
pubmed: 32115628
AIDS. 2022 Mar 1;36(3):459-471
pubmed: 34750289
PLoS One. 2012;7(8):e38334
pubmed: 22912660
Sex Health. 2009 Mar;6(1):83-6
pubmed: 19254497
Lancet Infect Dis. 2015 Jul;15(7):810-8
pubmed: 26070969
AIDS. 2000 Jul 7;14(10):1309-16
pubmed: 10930144
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):348-355
pubmed: 27351889
PLoS One. 2013 Dec 18;8(12):e81355
pubmed: 24367482
J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S73-8
pubmed: 14562861
Clin Infect Dis. 2011 Dec;53(11):1120-6
pubmed: 21998278
Lancet. 1998 Nov 28;352(9142):1725-30
pubmed: 9848347
HIV Med. 2017 Feb;18(2):89-103
pubmed: 27385511
PLoS One. 2017 Oct 23;12(10):e0186638
pubmed: 29059202
Euro Surveill. 2004 Oct;9(10):34-7
pubmed: 15507728
J Int AIDS Soc. 2018 Mar;21(3):e25100
pubmed: 29603879
AIDS. 2013 May 15;27(8):1245-51
pubmed: 23276809
PLoS One. 2015 Apr 13;10(4):e0118531
pubmed: 25874806
JAMA Netw Open. 2020 Jun 1;3(6):e207954
pubmed: 32539152
J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):39-46
pubmed: 27028501
Med Care. 2022 Sep 1;60(9):655-664
pubmed: 35880776
PLoS One. 2019 Mar 13;14(3):e0213526
pubmed: 30865722
AIDS Care. 2021 Apr;33(4):453-461
pubmed: 32106695
AIDS. 2017 Jan 28;31(3):427-436
pubmed: 27831953